Low ferroportin expression in AML is correlated with good risk cytogenetics, improved outcomes and increased sensitivity to chemotherapy.

Maura Gasparetto,Shanshan Pei,Mohammad Minhajuddin,Brett Stevens,Clayton A Smith,Paul Seligman

Leukemia Research（2019）

引用 16|浏览7

暂无评分

摘要

•AMLs with low levels of ferroportin (FPN) have improved outcomes.•Core Binding Factor AMLs have low levels of FPN compared to other AMLs.•Lower levels of FPN lead to an increased sensitivity to chemotherapy.•FPN may have prognostic significance and play a role in chemosensitivity.

查看译文

关键词

AML,LSCs,FPN,FCM,CT

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要